03501nam 22005891 450 991046477190332120200520144314.01-908986-59-X(CKB)3710000000083545(EBL)3410357(SSID)ssj0001084412(PQKBManifestationID)11975809(PQKBTitleCode)TC0001084412(PQKBWorkID)11022450(PQKB)11643876(MiAaPQ)EBC3410357(Au-PeEL)EBL3410357(CaPaEBR)ebr10827988(CaONFJC)MIL577719(OCoLC)923424667(EXLCZ)99371000000008354520090819d2010 uy 0engur|n|---|||||txtccrEvidence-based management of lipid disorders /Maud N. Vissers, John J.P. Kastelein, Erik S. Stroes, [editors]Harley :TFM,2010.1 online resource (322 p.)Description based upon print version of record.1-903378-71-0 Includes bibliographical references and index.""COVER FRONT""; ""Contents""; ""Foreword""; ""Contributors""; ""Acknowledgements""; ""Using evidence-based medicine""; ""Chapter 1 How much evidence is enough?""; ""Chapter 2 A brief review of lipoprotein metabolism""; ""Chapter 3 Epidemiological aspects of lipid and lipoprotein levels in relation to cardiovascular diseases""; ""Chapter 4 Are LDL cholesterol-lowering functional food ingredients successful in the long term?""; ""Chapter 5 Evidence-based treatment of primary hypo- and hypercholesterolemic disorders""; ""Chapter 6 Does raising HDL protect against atherosclerosis?""""Chapter 7 How do we diagnose hypertriglyceridemia in clinical practice and what are the consequences for treatment?""""Chapter 8 The optimal treatment of patients with familial combined hyperlipidemia""; ""Chapter 9 How to manage lipid and lipoprotein disorders in children""; ""Chapter 10 Contribution of the atherogenic dyslipidemic phenotype to the increased cardiovascular disease risk of the metabolic syndrome and diabetes mellitus""; ""Chapter 11 What are the consequences of renal insufficiency or the nephrotic syndrome for lipid levels?""""Chapter 12 The link between chronic inflammatory diseases and cardiovascular risk""""Chapter 13 What is the evidence for a physiological and pathogenic role of lipoprotein (a)?""; ""Chapter 14 Sitosterolemia; xenophobia for the body""; ""Chapter 15 How can we deal with inborn errors in cholesterol and bile acid biosynthesis?""; ""Chapter 16 Differential diagnosis of patients with xanthomas and xanthelasmata""; ""Chapter 17 When should we fear statin interactions?""; ""Chapter 18 What are the considerations in patients who are statin �intolerant�?""; ""Index""; ""COVER BACK""LipidsMetabolismDisordersTreatmentEvidence-based medicineElectronic books.LipidsMetabolismDisordersTreatment.Evidence-based medicine.616.399706Vissers Maud N882905Kastelein John J. P882906Stroes Erik S882907MiAaPQMiAaPQMiAaPQBOOK9910464771903321Evidence-based management of lipid disorders1972358UNINA